clonoSEQ Assay

DEVICE2 trials

Sponsors

Adaptive Biotechnologies, University of California, San Francisco

Conditions

Acute Lymphoblastic Leukemia, Adult B-CellChronic Lymphocytic LeukemiaMantle Cell LymphomaMultiple MyelomaNon-hodgkin Lymphoma

Phase 2

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

RecruitingNCT06252675

University of California, San FranciscoMantle Cell Lymphoma

Start: 2024-06-11End: 2028-07-31Target: 30Updated: 2025-10-22

Unknown Phase

The clonoSEQ® Watch Registry

TerminatedNCT04545333

Adaptive BiotechnologiesAcute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma +1

Start: 2020-10-13End: 2023-10-01Updated: 2024-08-01

Related Papers

Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Blood2024-11-05

Update for the ‘Watch’ Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Blood2023-11-02

Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies

Blood2022-11-15